The Korean Journal of Physiology and Pharmacology

  • 제9권4호
  • /
  • Pages.215-221
  • /
  • 2005
  • /
  • 1226-4512(pISSN)
  • /
  • 2093-3827(eISSN)
대한약리학회 (The Korean Society of Pharmacology)
권호 표지

Androgen Hormone Inhibits Expression of iNOS and COX-2 Protein in Rat Vascular Smooth Muscle Cell

  • Bae, Hwa-Young (Deportment of Pediatrics, Ulsan University Hospital, College of Medicine, University of Ulsan) ;
  • Park, Ji-Eun (Department of Pharmacology, College of Medicine, Yeungnam University) ;
  • Jeon, Eun-Mi (Department of Pharmacology, College of Medicine, Yeungnam University) ;
  • Kang, Young-Jin (Department of Pharmacology, College of Medicine, Yeungnam University) ;
  • Lee, Kwang-Youn (Department of Pharmacology, College of Medicine, Yeungnam University) ;
  • Choi, Hyoung-Chul (Department of Pharmacology, College of Medicine, Yeungnam University)
  • 발행 : 2005.08.21
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We investigated the effects of testosterone and dihydrotestosterone on inflammatory response of iNOS and COX-2 expression in rat vascular smooth muscle cells. Rat vascular smooth muscle cells (VSMC) stimulated with bacterial lipopolysaccharide $(LPS;\;10{\mu}g/ml)$ for 24 hours were incubated with increasing amounts of testosterone and dihydrotestosterone (1 and 100 nM). LPS was found to induce inflammatory response of iNOS and COX-2 mRNA and protein in VSMC. These processes were affected by male sex steroid hormones. For 3 hours, however, pretreatment of the cells with 100 nM each of testosterone and dihydrotestosterone suppressed LPS induced iNOS and COX-2 protein expression. RT-PCR analysis revealed that testosterone and dihydrotestosterone did not inhibit mRNA expression of iNOS and COX-2 stimulated by 24 hours of LPS incubation. Proliferation rate was slower in VSMC treated with testosterone and dihydrotestosterone. Testosterone enhanced androgen receptor expression, and LPS significantly reduced androgen receptor protein expression in VSMC. These results indicate that the expression of both iNOS and COX-2 proteins was suppressed by testosterone and dihydrotestosterone in LPS stimulated VSMC and leading to reduction of vascular inflammation.

키워드

참고문헌

  1. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci 76: 2315-2328, 2005 https://doi.org/10.1016/j.lfs.2004.10.042
  2. Barzilay J, Freedland E. Inflammation and its association with glucose disorders and cardiovascular disease. Treat Endocrinol 2: 85-94, 2003 https://doi.org/10.2165/00024677-200302020-00002
  3. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002 https://doi.org/10.1002/jcp.10068
  4. Choi HC, Lee KY. CD14 glycoprotein expressed in vascular smooth muscle cells. J Pharmacol Sci 95: 65-70, 2004 https://doi.org/10.1254/jphs.95.65
  5. Choi HC, Lee SG, Kim JH, Kim JY, Sohn UD, Ha JH, Lee KY, Kim WJ. Lipopolysaccharide inhibits proliferation of the cultured vascular smooth muscle cells by stimulating inducible nitric oxide synthase and subsequent activation of guanylate cyclase. Korean J Physiol Pharmacol 5: 343-351, 2001
  6. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemiareperfusion injury in rat hearts. Cardiovasc Res 66: 462-471, 2005 https://doi.org/10.1016/j.cardiores.2005.02.008
  7. Ding AQ, Stallone JN. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves $K^{+}$ channel activation. J Appl Physiol 91: 2742-2750, 2001 https://doi.org/10.1152/jappl.2001.91.6.2742
  8. Di Rosa M, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 172: 1246-1252, 1990 https://doi.org/10.1016/0006-291X(90)91583-E
  9. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957, 2004 https://doi.org/10.1126/science.1103333
  10. Festa A, Haffner SM. Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111: 2414-2415, 2005 https://doi.org/10.1161/01.CIR.0000167558.77793.E8
  11. Greenberg SS, Jie O, Zhao X, Wang JF, Giles TD. The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol, in vivo. Alcohol Clin Exp Res 22(5 Suppl): 260S-265S, 1998 https://doi.org/10.1111/j.1530-0277.1998.tb04014.x
  12. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87: 3632-3639, 2002 https://doi.org/10.1210/jc.87.8.3632
  13. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103: 1382-1385, 2001 https://doi.org/10.1161/01.CIR.103.10.1382
  14. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio E, Udagawa Y. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26: 1419-1428, 2005
  15. Hashimura K, Sudhir K, Nigro J, Ling S, Williams MR, Komesaroff PA, Little PJ. Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. Endocrinology 146: 2085-2090, 2005 https://doi.org/10.1210/en.2004-1242
  16. Hutchison SJ, Sudhir K, Chou TM, Sievers RE, Zhu BQ, Sun YP, Deedwania PC, Glantz SA, Parmley WW, Chatterjee K. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. J Am Coll Cardiol 29: 800-807, 1997 https://doi.org/10.1016/S0735-1097(96)00570-0
  17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998 https://doi.org/10.1001/jama.280.7.605
  18. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 290: 69-73, 1995 https://doi.org/10.1016/0922-4106(95)90018-7
  19. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Long-term effects of finasteride on prostate tissue composition. Urology 53: 574-580, 1999 https://doi.org/10.1016/S0090-4295(98)00567-6
  20. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 167: 2105-2108, 2002 https://doi.org/10.1016/S0022-5347(05)65095-1
  21. Miki S, Takeyama N, Tanaka T, Nakatani T. Immune dysfunction in endotoxicosis: role of nitric oxide produced by inducible nitric oxide synthase. Crit Care Med 33: 716-720, 2005 https://doi.org/10.1097/01.CCM.0000159200.69314.3A
  22. Nachtigal P, Kopecky M, Solichova D, Zdansky P, Semecky V. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 57: 197-203, 2005 https://doi.org/10.1211/0022357055353
  23. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68: 341-350, 2004 https://doi.org/10.1016/j.bcp.2004.03.029
  24. Oka M, Maeda S, Koga N, Kato K, Saito T. A modified colorimetric MTT assay adapted for primary cultured hepatocytes: application to proliferation and cytotoxicity assays. Biosci Biotechnol Biochem 56: 1472-1473, 1992 https://doi.org/10.1271/bbb.56.1472
  25. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 90: 2708-2711, 2005 https://doi.org/10.1210/jc.2004-2011
  26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-833, 2002 https://doi.org/10.1001/jama.288.3.321
  27. Sainz J, Osuna A, Wangensteen R, de Dios Luna J, Rodriguez- Gomez I, Duarte J, Moreno JM, Vargas F. Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension. Exp Physiol 89: 155-162, 2004. https://doi.org/10.1113/expphysiol.2003.002652
  28. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999 https://doi.org/10.1016/S0002-9440(10)65230-3
  29. Shimomura-Shimizu M, Sugiyama KI, Muroi M, Tanamoto KI. Alachlor and carbaryl suppress lipopolysaccharide-induced iNOS expression by differentially inhibiting NF-kappaB activation. Biochem Biophys Res Commun 332: 793-799, 2005 https://doi.org/10.1016/j.bbrc.2005.05.024
  30. Stemme V, Swedenborg J, Claesson H, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20: 146-152, 2000 https://doi.org/10.1053/ejvs.2000.1145
  31. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl 22: 300-306, 1999 https://doi.org/10.1046/j.1365-2605.1999.00184.x
  32. Teoh H, Quan A, Man RY. Acute impairment of relaxation by low levels of testosterone in porcine coronary arteries. Cardiovasc Res 45: 1010-1018, 2000 https://doi.org/10.1016/S0008-6363(99)00398-3
  33. Valenti S, Fazzuoli L, Giusti M. Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. J Endocrinol Invest 26: 522-526, 2003 https://doi.org/10.1007/BF03345214
  34. Vane JR. COX-2 inhibitors: background knowledge for clinical use. Introduction. Inflamm Res 47: S77, 1998 https://doi.org/10.1007/s000110050283
  35. Vo PA, Lad B, Tomlinson JA, Francis S, Ahluwalia A. Autoregulatory role of endotheliumderived nitric oxide (NO) on Lipopolysaccharide- induced vascular inducible NO synthase expression and function. J Biol Chem 280: 7236-7243, 2005 https://doi.org/10.1074/jbc.M411317200
  36. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 329: 247-256, 1993 https://doi.org/10.1056/NEJM199312303292704
  37. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 87: 176-181, 2002 https://doi.org/10.1210/jc.87.1.176
  38. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91: 1154-1160, 1995 https://doi.org/10.1161/01.CIR.91.4.1154